Nondietary Therapies for Celiac Disease

Gastrointestinal Endoscopy Clinics of North America

Volumn 22, Issue 4, 2012, Pages 811-831

  Mukherjee, Rupa ^a   Kelly, Ciaran P ^a   Schuppan, Detlef ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Gliadin; Gluten vaccination; Gluten free diet; Immunity; Interferon ; Nondietary therapies; Tissue transglutaminase; TNF

Indexed keywords

ADALIMUMAB; AMG 714; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; FONTOLIZUMAB; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIADIN; GLUTEN; HLA ANTIGEN CLASS 2; HLA DQ2 ANTIGEN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; NATALIZUMAB; OTELIXIZUMAB; PROLYL ENDOPEPTIDASE; PROTEINASE; RECOMBINANT INTERLEUKIN 10; RITUXIMAB; TEPLIZUMAB; TOSITUMOMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VEDOLIZUMAB; VISILIZUMAB;

BONE MARROW TRANSPLANTATION; CELIAC DISEASE; ENVIRONMENTAL FACTOR; GLUTEN FREE DIET; HEREDITY; IMMUNE RESPONSE; IMMUNOGENICITY; LACTOCOCCUS LACTIS; LYMPHOCYTE PROLIFERATION; NECATOR AMERICANUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHEAT;

CELIAC DISEASE; HUMANS;

EID: 84867683114     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2012.09.001     Document Type: Review

References (104)

1. Di Sabatino A., Corazza G.R. Coeliac disease. Lancet 2009, 373:1480-1493.
2. Maki M., Mustalahti K., Kokkonen J., et al. Prevalence of celiac disease among children in Finland. N Engl J Med 2003, 348:2517-2524.
3. Fasano A., Berti I., Gerarduzzi T., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003, 163:286-292.
4. Schuppan D., Junker Y., Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009, 137:1912-1933.
5. Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000, 119:234-242.
6. Sollid L.M. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002, 2:647-655.
7. Maiuri L., Ciacci C., Ricciardelli I., et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005, 129:1400-1413.
8. Gianfrani C., Auricchio S., Troncone R. Adaptive and innate immune responses in celiac disease. Immunol Lett 2005, 99:141-145.
9. Sollid L.M., Khosla C. Novel therapies for coeliac disease. J Intern Med 2011, 269:604-613.
10. Dubois P.C., Trynka G., Franke L., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010, 42:295-302.
11. van Heel D.A., Franke L., Hunt K.A., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39:827-829.
12. Petronzelli F., Bonamico M., Ferrante P., et al. Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann Hum Genet 1997, 61:307-317.
13. Elli L., Bergamini C.M., Bardella M.T., et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009, 41:541-550.
14. Dieterich W., Ehnis T., Bauer M., et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3:797-801.
15. Aeschlimann D., Thomazy V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 2000, 41:1-27.
16. Shan L., Molberg O., Parrot I., et al. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297:2275-2279.
17. Fasano A., Not T., Wang W., et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000, 355:1518-1519.
18. Clemente M.G., De Virgiliis S., Kang J.S., et al. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut 2003, 52:218-223.
19. Schumann M., Richter J.F., Wedell I., et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 2008, 57:747-754.
20. Man A.L., Prieto-Garcia M.E., Nicoletti C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?. Immunology 2004, 113:15-22.
21. Rashtak S., Murray J.A. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther 2012, 35:768-781.
22. Akobeng A.K., Thomas A.G. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008, 27:1044-1052.
23. Lanzini A., Lanzarotto F., Villanacci V., et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009, 29:1299-1308.
24. Aziz I., Evans K.E., Papageorgiou V., et al. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet?. J Gastrointestin Liver Dis 2011, 20:27-31.
25. Troncone R., Ivarsson A., Szajewska H., et al. Review article: future research on coeliac disease - a position report from the European multistakeholder platform on coeliac disease (CDEUSSA). Aliment Pharmacol Ther 2008, 27:1030-1043.
26. Auricchio S., De Ritis G., De Vincenzi M., et al. Effects of gliadin-derived peptides from bread and durum wheats on small intestine cultures from rat fetus and coeliac children. Pediatr Res 1982, 16:1004-1010.
27. Frisoni M., Corazza G.R., Lafiandra D., et al. Wheat deficient in gliadins: promising tool for treatment of coeliac disease. Gut 1995, 36:375-378.
28. Zandonadi R.P., Botelho R.B., Araujo W.M. Psyllium as a substitute for gluten in bread. J Am Diet Assoc 2009, 109:1781-1784.
29. van Herpen T.W., Goryunova S.V., van der Schoot J., et al. Alpha-gliadin genes from the A, B, and D genomes of wheat contain different sets of celiac disease epitopes. BMC Genomics 2006, 7:1.
30. Di Cagno R., De Angelis M., Lavermicocca P., et al. Proteolysis by sourdough lactic acid bacteria: effects on wheat flour protein fractions and gliadin peptides involved in human cereal intolerance. Appl Environ Microbiol 2002, 68:623-633.
31. Di Cagno R., De Angelis M., Auricchio S., et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004, 70:1088-1096.
32. Rizzello C.G., De Angelis M., Di Cagno R., et al. Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease. Appl Environ Microbiol 2007, 73:4499-4507.
33. Yokoyama K., Nio N., Kikuchi Y. Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol 2004, 64:447-454.
34. Stepniak D., Spaenij-Dekking L., Mitea C., et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006, 291:G621-G629.
35. Pyle G.G., Paaso B., Anderson B.E., et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 2005, 3:687-694.
36. Marti T., Molberg O., Li Q., et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005, 312:19-26.
37. Pyle G.G., Paaso B., Anderson B.E., et al. Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses. Clin Gastroenterol Hepatol 2005, 3:679-686.
38. Mitea C., Havenaar R., Drijfhout J.W., et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008, 57:25-32.
39. Gass J., Vora H., Bethune M.T., et al. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther 2006, 318:1178-1186.
40. Gass J., Bethune M.T., Siegel M., et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007, 133:472-480.
41. Ehren J., Moron B., Martin E., et al. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One 2009, 4:e6313.
42. Siegel M., Garber M.E., Spencer A.G., et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012, 57:440-450.
43. Tye-Din J.A., Anderson R.P., Ffrench R.A., et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010, 134:289-295.
44. Liang L., Pinier M., Leroux J.C., et al. Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease. Biopolymers 2010, 93:418-428.
45. Pinier M., Verdu E.F., Nasser-Eddine M., et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009, 136:288-298.
46. Warny M., Fatimi A., Bostwick E.F., et al. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999, 44:212-217.
47. Elliott D.E., Summers R.W., Weinstock J.V. Helminths as governors of immune-mediated inflammation. Int J Parasitol 2007, 37:457-464.
48. Summers R.W., Elliott D.E., Urban J.F., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825-832.
49. Daveson A.J., Jones D.M., McSorley H., et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomized double-blinded placebo controlled trial. PLoS One 2011, 6(3):e17366.
50. McSorley H.J., Gaze S., Daveson J., et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 2011, 6(9):e24092.
51. Maurano F., Siciliano R.A., De Giulio B., et al. Intranasal administration of one alpha gliadin can downregulate the immune response to whole gliadin in mice. Scand J Immunol 2001, 53:290-295.
52. Marietta E.V., David C.S., Murray J.A. Important lessons derived from animal models of celiac disease. Int Rev Immunol 2011, 30:197-206.
53. Senger S., Luongo D., Maurano F., et al. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 2003, 88:127-134.
54. Huibregtse I.L., Marietta E.V., Rashtak S., et al. Induction of antigen-specific tolerance by oral administration of lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009, 183:2390-2396.
55. van Elburg R.M., Uil J.J., Mulder C.J., et al. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 1993, 34:354-357.
56. Sapone A., de Magistris L., Pietzak M., et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006, 55:1443-1449.
57. Drago S., El Asmar R., Di Pierro M., et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006, 41:408-419.
58. Duerksen D.R., Wilhelm-Boyles C., Veitch R., et al. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet. Dig Dis Sci 2010, 55:1026-1031.
59. Tripathi A., Lammers K.M., Goldblum S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 2009, 106:16799-16804.
60. Paterson B.M., Lammers K.M., Arrieta M.C., et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007, 26:757-766.
61. Kelly C.P., Green P.H., Murray J.A., et al. Intestinal permeability of larazotide acetate in celiac disease: results of a phase IIB, 6-week gluten-challenge clinical trial. Gastroenterology 2009, 136(Suppl 1):M2048. [abstract].
62. Beaurepaire C., Smyth D., McKay D.M. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 2009, 29:133-144.
63. Chaturvedi L.S., Marsh H.M., Basson M.D. Role of RhoA and its effectors ROCK and mDia1 in the modulation of deformation-induced FAK, ERK, p38, and MLC motogenic signals in human Caco-2 intestinal epithelial cells. Am J Physiol Cell Physiol 2011, 301:C1224-C1238.
64. McKerracher L., Higuchi H. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 2006, 23:309-317.
65. LoGrasso P.V., Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009, 9:704-723.
66. Zhao J., de Vera J., Narushima S., et al. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology 2007, 132:1331-1343.
67. Esposito C., Caputo I., Troncone R. New therapeutic strategies for coeliac disease: tissue transglutaminase as a target. Curr Med Chem 2007, 14:2572-2580.
68. Molberg O., McAdam S., Lundin K.E., et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001, 31:1317-1323.
69. Choi K., Siegel M., Piper J.L., et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005, 12:469-475.
70. Silano M., Di Benedetto R., Maialetti F., et al. A 10-residue peptide from durum wheat promotes a shift from a Th1-type response toward a Th2-type response in celiac disease. Am J Clin Nutr 2008, 87:415-423.
71. Silano M., Leonardi F., Trecca A., et al. Prevention by a decapeptide from durum wheat of in vitro gliadin peptide-induced apoptosis in small-bowel mucosa from coeliac patients. Scand J Gastroenterol 2007, 42:786-787.
72. Silano M., Di Benedetto R., Trecca A., et al. A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res 2007, 61:67-71.
73. Biagi F., Ellis H.J., Parnell N.D., et al. A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?. Aliment Pharmacol Ther 1999, 13:945-950.
74. Xia J., Bergseng E., Fleckenstein B., et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007, 15:6565-6573.
75. Kapoerchan V.V., Wiesner M., Hillaert U., et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol Immunol 2010, 47:1091-1097.
76. Berlin C., Berg E.L., Briskin M.J., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
77. Rivera-Nieves J., Ho J., Bamias G., et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006, 131:1518-1529.
78. Walters M.J., Wang Y., Lai N., et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010, 335:61-69.
79. Ghosh S., Goldin E., Gordon F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
80. Parikh A., Leach T., Wyant T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2011, 18(8):1470-1479.
81. Villablanca E.J., Cassani B., von Andrian U.H., et al. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011, 140:1776-1784.
82. Booth V., Keizer D.W., Kamphuis M.B., et al. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002, 41:10418-10425.
83. Di Sabatino A., Rovedatti L., Vetrano S., et al. Involvement of CD40-CD40 ligand in uncomplicated and refractory celiac disease. Am J Gastroenterol 2011, 106:519-527.
84. Ciccocioppo R., Di Sabatino A., Bauer M., et al. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 2005, 85:397-407.
85. Pender S.L., Tickle S.P., Docherty A.J., et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997, 158:1582-1590.
86. Reinisch W., de Villiers W., Bene L., et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010, 16:233-242.
87. Gillett H.R., Arnott I.D., McIntyre M., et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002, 122:800-805.
88. Costantino G., della Torre A., Lo Presti M.A., et al. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008, 40:74-77.
89. Yokoyama S., Watanabe N., Sato N., et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A 2009, 106:15849-15854.
90. Braat H., Rottiers P., Hommes D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-759.
91. Salvati V.M., Mazzarella G., Gianfrani C., et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 2005, 54:46-53.
92. Mulder C.J., Wahab P.J., Meijer J.W., et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001, 13:1183-1188.
93. Herold K.C., Gitelman S., Greenbaum C., et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009, 132:166-173.
94. Wiczling P., Rosenzweig M., Vaickus L., et al. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010, 50:494-506.
95. Hale G., Rebello P., Al Bakir I., et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010, 50:1238-1248.
96. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
97. Mei H.E., Frolich D., Giesecke C., et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 2010, 116:5181-5190.
98. Abdallah H., Leffler D., Dennis M., et al. Refractory celiac disease. Curr Gastroenterol Rep 2007, 9:401-405.
99. Al-Toma A., Goerres M.S., Meijer J.W., et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006, 4:1322-1327. [quiz: 1300].
100. Tack G.J., Verbeek W.H., Al-Toma A., et al. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011, 17:506-513.
101. Tack G.J., Wondergem M.J., Al-Toma A., et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 2011, 46:840-846.
102. Al-Toma A., Verbeek W.H., Visser O.J., et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007, 39:634-641.
103. Al-toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007, 109:2243-2249.
104. Garcia-Castro J., Trigueros C., Madrenas J., et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008, 12:2552-2565.